sever
pneumoniaassoci
respiratori
syndrom
caus
new
coronaviru
identifi
decemb
spread
rapidli
becom
worldwid
public
health
challeng
patient
experienc
sever
complic
includ
acut
respiratori
distress
syndrom
ard
even
progress
intens
care
unit
icu
admiss
die
explor
mortal
caus
advanc
novel
therapeut
develop
sever
crucial
moment
biopsi
sampl
analysi
autopsi
suggest
increas
alveolar
exud
caus
aberr
host
immun
respons
inflammatori
cytokin
storm
probabl
imped
alveolar
ga
exchang
contribut
high
mortal
sever
patient
research
identifi
pathogen
cell
inflammatori
monocyt
incit
inflammatori
storm
larg
amount
interleukin
therefor
monoclon
antibodi
target
pathway
may
potenti
curb
inflammatori
storm
moreov
tocilizumab
treatment
block
receptor
show
inspir
clinic
result
includ
temperatur
return
normal
quickli
respiratori
function
improv
therefor
suggest
tocilizumab
effect
treatment
sever
patient
calm
inflammatori
storm
reduc
mortal
past
decad
two
known
pathogen
human
coronavirus
sever
acut
respiratori
syndrom
cov
sarscov
middl
east
respiratori
syndrom
cov
merscov
report
damag
respiratori
tract
caus
high
morbid
mortal
sever
acut
respiratori
syndrom
coronaviru
newli
discov
coronaviru
report
decemb
citi
wuhan
hubei
provinc
china
march
case
report
fatal
case
accord
chines
center
diseas
control
prevent
cdc
meanwhil
case
report
fatal
case
countri
except
china
itali
date
infect
death
global
outbreak
caus
corona
viru
diseas
seem
inevit
among
patient
common
symptom
includ
fever
cough
myalgia
fatigu
onset
major
patient
recov
howev
patient
progress
sever
complic
includ
acut
respiratori
distress
syndrom
ard
may
worsen
rapidli
respiratori
failur
need
intens
care
unit
icu
even
caus
multipl
organ
failur
therefor
explor
mortal
caus
advanc
novel
therapeut
develop
sever
crucial
import
moment
although
virusinduc
cytopath
effect
viral
evas
host
immun
respons
believ
import
diseas
sever
studi
human
die
journal
translat
medicin
sar
mer
suggest
aberr
host
immun
respons
result
inflammatori
cytokin
storm
lethal
diseas
similar
inflammatori
cytokin
sar
mer
patient
also
increas
plasma
concentr
inflammatori
cytokin
tumour
necrosi
factor
interleukin
il
granulocytecoloni
stimul
factor
gcsf
monocyt
chemoattract
protein
macrophag
inflammatori
protein
alpha
protein
especi
icu
patient
impli
cytokin
storm
occur
moreov
patient
decreas
lymphocyt
peripher
blood
characterist
pulmonari
ground
glass
chang
imag
importantli
biopsi
sampl
autopsi
patient
die
histolog
examin
show
bilater
diffus
alveolar
damag
includ
edema
proteinac
exud
focal
reactiv
hyperplasia
pneumocyt
patchi
inflammatori
cellular
infiltr
multinucl
giant
cell
also
recov
autopsi
examin
type
ii
alveolar
epitheli
cell
prolifer
markedli
cell
exfoli
alveolar
septum
hyperem
edemat
clear
intravascular
thrombosi
focal
monocyt
lymphocyt
plasma
cell
infiltr
pulmonari
interstitium
immunohistochemistri
result
show
posit
immun
cell
includ
phenomena
suggest
sever
pulmonari
inflammatori
immun
cell
exist
infect
therefor
increas
alveolar
exud
caus
aberr
host
immun
respons
inflammatori
cytokin
storm
probabl
imped
alveolar
ga
exchang
contribut
high
mortal
sever
patient
inflammatori
storm
refer
excess
inflammatori
respons
flare
control
immun
system
gone
awri
identifi
kind
immun
cell
involv
inflammatori
cytokin
critic
target
sever
patient
analyz
peripher
blood
sampl
patient
sever
critic
first
affili
hospit
univers
scienc
technolog
china
observ
monocyt
cell
sever
critic
patient
decreas
significantli
compar
normal
control
aberr
pathogen
cell
critic
icu
care
patient
show
activ
characterist
accompani
coexpress
gmcsf
phenomenon
arous
alarm
gmcsf
capabl
control
divers
pathogen
capabl
inflammatori
myeloid
cell
especi
monocyt
expect
inflammatori
monocyt
phenotyp
exist
peripher
blood
patient
larger
popul
critic
patient
icu
note
without
restimul
pma
incub
monensin
larg
amount
could
test
inflammatori
monocyt
especi
icu
patient
therefor
pathogen
cell
gmcsf
inflammatori
monocyt
high
express
exist
especi
critic
icu
patient
given
larg
amount
mononuclear
inflammatori
lymphocyt
observ
biopsi
sampl
autopsi
patient
believ
pathogen
cell
inflammatori
monocyt
may
enter
pulmonari
circul
larg
number
incit
inflammatori
storm
sever
critic
patient
fig
tocilizumab
first
market
block
antibodi
target
receptor
prove
safeti
effect
therapi
rheumatoid
arthriti
fig
order
verifi
whether
target
may
potenti
effect
safe
way
reduc
mortal
patient
diagnos
sever
critic
first
affili
hospit
univers
scienc
technolog
china
anhui
fuyang
second
peopl
hospit
recruit
given
tocilizumab
therapi
tabl
patient
receiv
standard
treatment
accord
diagnosi
treatment
protocol
th
edit
includ
lopinavir
methylprednisolon
symptom
reliev
oxygen
therapi
result
tocilizumab
treatment
inspir
temperatur
patient
return
normal
quickli
respiratori
function
symptom
improv
remark
among
patient
patient
recov
discharg
within
week
tocilizumab
therapi
one
left
patient
recov
icu
care
advers
drug
reaction
report
treatment
tocilizumab
promis
preliminari
clinic
result
launch
multicent
largescal
clinic
trial
alreadi
sever
critic
patient
treat
way
immunotherapi
strategi
tocilizumab
treatment
formal
includ
diagnosi
treatment
program
edit
nation
health
commiss
china
sinc
march
follow
tocilizumab
use
patient
extens
bilater
lung
lesion
opac
sever
critic
patient
elev
laboratori
detect
level
first
dose
mg
kg
recommend
dose
mg
dilut
ml
normal
salin
infus
time
h
patient
poor
initi
efficaci
addit
applic
made
h
dose
maximum
number
time
administr
two
maximum
dose
singl
dose
exceed
mg
note
patient
allerg
reaction
tuberculosi
activ
infect
contraind
suggest
concentr
detect
fever
persist
day
chemiluminesc
detect
serum
content
pgml
tocilizumab
use
temporarili
increas
serum
next
day
receptor
block
tocilizumab
togeth
tocilizumab
treatment
recommend
reduc
mortal
sever
three
coronavirus
includ
sarscov
merscov
induc
aberr
noneffect
host
immun
respons
associ
sever
lung
patholog
new
addit
caus
seriou
alveolar
mucu
infiltr
multipl
organ
failur
continu
spread
number
fatal
case
rise
exponenti
mani
countri
advanc
novel
therapeut
develop
becom
crucial
minim
number
death
absenc
specif
antivir
drug
exist
hostdirect
therapi
could
potenti
repurpos
treat
china
plan
tocilizumab
treatment
shown
remark
effect
safeti
clinic
practic
past
month
hope
benefit
countri
fight
pandem
reduc
mortal
sever
well
readi
submit
research
choos
bmc
benefit
receiv
march
accept
april
